Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2774494 | 1.00 | MAPT (0.55) | MAPTSMN1; SMN2ESR2MAOBLMNA | |
| SCHEMBL10710069 | 1.00 | MAPT (0.55) | MAPTSMN1; SMN2ESR2MAOBLMNA | |
| SCHEMBL24959113 | 0.83 | CA3 (0.46) | MAPTSMN1; SMN2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL2316355 | 0.82 | MAOB (0.43) | MAPTSMN1; SMN2MAOBLMNAAR | |
| SCHEMBL2924111 | 0.81 | NFE2L2 (0.48) | MAPTSMN1; SMN2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL1968882 | 0.81 | NFE2L2 (0.48) | MAPTSMN1; SMN2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL1968880 | 0.81 | NFE2L2 (0.48) | MAPTSMN1; SMN2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL8821790 | 0.80 | CA2 (0.55) | MAPTSMN1; SMN2MAOBALDH1A1AR | |
| SCHEMBL8821791 | 0.80 | CA2 (0.55) | MAPTSMN1; SMN2MAOBALDH1A1AR | |
| Hydrochloric Acid SCHEMBL28115149 | 0.79 | NFE2L2 (0.47) | MAPTSMN1; SMN2LMNAALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-59134767-A | — | — | None | — | — | JP | disclosed |
| JP-59161349-A | — | — | None | — | — | JP | disclosed |
| US-8546374-B2 | Amino-tetrazoles analogues and methods of use | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120329772-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2012-12-27 | — | — | US | disclosed |
| US-8217067-B2 | Antiinflammatory agents, antidepressants, analgesics, purinergic receptor antagonists; neurodegenerative diseases, spinal cord injuries; 1-(2,3-dichlorophenyl)-N-[(2-methylphenyl)methyl]-1H-tetraazol-5-amine | ABBOTT LABORATORIES (US) | 2012-07-10 | — | — | US | disclosed |
| CN-102046618-A | Hydroxyquinoxalinecarboxamide derivative | DAIICHI SANKYO CO LTD | 2011-05-04 | — | — | CN | disclosed |
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2258697-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-12-08 | — | — | EP | disclosed |
| US-7723367-B2 | Amino-tetrazoles analogues and methods of use | ABBOTT LABORATORIES (US) | 2010-05-25 | — | — | US | disclosed |
| US-7704997-B1 | Amino-tetrazole analogues and methods of use | ABBOTT LABORATORIES (US) | 2010-04-27 | — | — | US | disclosed |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | ABBVIE INC. | 2006-03-09 | — | — | US | disclosed |
| WO-2005111003-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2005-11-24 | — | — | WO | disclosed |
| EP-0152014-B1 | 2-CYANO-4-HALOGENOPHENYL SUBSTITUTED-BENZOATES AND LIQUID CRYSTAL COMPOSITIONS CONTAINING THEM | Chisso Corporation (JP) | 1988-04-20 | — | — | EP | disclosed |
| US-4659501-A | LIQUID CRYSTALS | CHISSO CORPORATION (JP) | 1987-04-21 | — | — | US | disclosed |
| US-4603018-A | NEGATIVE DIELECTRIC ANISOTROPIC LIQUID CRYSTALS | CHISSO CORPORATION (JP) | 1986-07-29 | — | — | US | disclosed |
| EP-0106588-B1 | 2-CYANO-4-HALOGENOPHENYL ESTERS | Chisso Corporation (JP) | 1986-04-30 | — | — | EP | disclosed |
| EP-0152014-A2 | 2-Cyano-4-halogenophenyl substituted-benzoates and liquid crystal compositions containing them | Chisso Corporation (JP) | 1985-08-21 | — | — | EP | disclosed |
| JP-S59161349-A | LIQUID CRYSTAL COMPOUND WITH NEGATIVE DIELECTRIC ANISOTROPY | CHISSO CORP | 1984-09-12 | — | — | JP | disclosed |
| JP-S59134767-A | ESTER COMPOUND HAVING NEGATIVE DIELECTRIC ANISOTROPY | CHISSO CORP | 1984-08-02 | — | — | JP | disclosed |
| EP-0106588-A1 | 2-Cyano-4-halogenophenyl esters | Chisso Corporation (JP) | 1984-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329772-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | P2RX7, P2RX2, P2RX5 | MAPT 3496/4885SMN1; SMN2 3761/4885ESR2 861/4885 |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | P2RX7, P2RX2, P2RX3 | MAPT 3341/4885SMN1; SMN2 3742/4885ESR2 980/4885 |
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | F12, F2, C3AR1 | MAPT 4885/4885SMN1; SMN2 4169/4885ESR2 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.